TMPRSS2 and posterior cortical atrophy: Our data support the effectiveness of rucaparib as a potent PARPi for radiosensitizing PCa cells, most effectively when used at low dose-rates in cells that harbor the TMPRSS2-ERG gene fusion or are PTEN-deficient.